Sera Prognostics (Salt Lake City, UT) a development-stage diagnostic company focused on preterm birth and other pregnancy complications, closed a $19.3M Series A financing. Participants include InterWest Partners, Domain Associates, Catalyst Health Ventures, UpStart Life Sciences Capital and Osage University Partners.

Neuronetics (Malvern, PA) a commercial-stage medical device company focused on pulsed magnetic field stimulation for non-invasive, non-systemic treatment of depression, closed a $30M Series E financing. Participants include Polaris Venture Partners, Pfizer Venture Investments, Investor Growth Capital, New Leaf Venture Partners, Interwest Partners, Three Arch Partners, Quaker BioVentures and Onset Ventures.

Tesaro (Boston, MA) a clinical-stage biopharmaceutical focused on chemotherapy induced nausea and non-small cell lung cancer, closed a $101M Series B financing. Participants include New Enterprise Associates, InterWest Partners, T. Rowe Price, Pappas Ventures, Oracle Partners, Deerfield Capital Management and Leerink Swann.

Glaukos (Laguna Hills, CA) a clinical-stage ophthalmology medical device company focused on the management of open-angle glaucoma, closed a $29.5M Series E. Participants include OrbiMed, Frazier Healthcare Ventures, InterWest Partners, Domain Associates and Versant Ventures.

Doximity (San Mateo) a healthcare technology company focused on developing a physician-to-physician communication platform, closed a $10.8M Series A financing. Participants include Emergence Capital Partners and InterWest Partners.

ReVision Optics (Lake Forest, CA) a clinical-stage medical device company focused on a corneal inlay for presbyopia, closed a $35M Series D financing. Participants include ProQuest Investments, Domain Associates, Canaan Partners and InterWest Partners.

MicroCHIPS (Bedford, MA) a development-stage medical device company focused on implantable drug delivery and biosensing for diabetes and osteoporosis, closed a $16.5M Series C financing. Participants include InterWest Partners, Polaris Venture Partners, Novartis Venture Fund, Flybridge Capital Partners, Medtronic, Saints Capital, Intersouth Partners, Care Capital and CSK Venture Capital.

Integrated Diagnostics (Seattle, WA) a development-stage diagnostics company focused on rapid biomarker validation and parallel organ-centric assays, closed a $30M Series A financing. Participants include Interwest Partners, The Wellcome Trust and Dievini Hopp Biotech Holding. Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

PrimeraDx (Mansfield, MA) a development-stage molecular diagnostics company focused on automated multiplexed assays of infectious disease testing in immune compromised patients undergoing solid organ and bone marrow transplant, closed a $20M Series C financing. Participants include CHL Medical Partners, Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Co. and Invus.